Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

Sarepta Therapeutics sells 9.3M Arrowhead shares for $174M and fulfills a $100M milestone payment. Read more here.

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Sarepta Therapeutics, the US biotech, has sold around 9.3 million shares of Arrowhead Pharmaceuticals in a privately ...

Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquefied its entire stake in the smaller biotech ...

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock fell 6% following Sarepta Therapeutics’ (NASDAQ:SRPT) sale of over 9.2 ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

It is a rough day to be an investor in Arrowhead Pharmaceuticals (NASDAQ: ARWR). Shares of the clinical-stage biotech are collapsing, falling more than 65% as of 11:36 a.m. EST on Tuesday in ...

What happened Shares of clinical-stage biotech company Arrowhead Pharmaceuticals (ARWR -0.97%) were up more than 17% Tuesday morning after the company released interim results from a phase 1/2 trial.

If so, you'll want to check out Arrowhead Pharmaceuticals (ARWR -0.97%). SVB Securities, a subsidiary of SVB Financial, recently gave the stock an upgrade to outperform and raised its price target.

What happenedShares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) are getting pummeled in response to bad news for the company's experimental cystic fibrosis therapy. Investors unhappy about a ...